English Eftilagimod alpha Cited by user Bioguy556 on 02 Feb 2020 Eftilagimod alpha (INN; development code IMP321 or efti) is a large-molecule cancer drug being developed by the clinical-stage biotechnology company Immutep.
English Prima BioMed Cited by user Rjwilmsi on 14 Dec 2016 Prima BioMed Ltd is a biotechnology company working primarily in the field of cancer immunotherapy.
English Frédéric Triebel Cited by user OzBioMan on 30 Apr 2015 Frédéric Triebel (born 20 November 1954) is a French immunologist who is best known for his 1990 discovery of the LAG3 immune control mechanism.
English IMP321 Cited by user OzBioMan on 29 Apr 2015 IMP321 is a large molecule cancer drug being developed by the clinical stage biotechnology company Prima BioMed (Nasdaq: PBMD).